Aflibercept (Eylea, BAY86-5321)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Central Retinal Vein Occlusion
Conditions
Central Retinal Vein Occlusion
Trial Timeline
Jun 10, 2016 → Jul 31, 2019
NCT ID
NCT02800642About Aflibercept (Eylea, BAY86-5321)
Aflibercept (Eylea, BAY86-5321) is a approved stage product being developed by Bayer for Central Retinal Vein Occlusion. The current trial status is completed. This product is registered under clinical trial identifier NCT02800642. Target conditions include Central Retinal Vein Occlusion.
What happened to similar drugs?
3 of 19 similar drugs in Central Retinal Vein Occlusion were approved
Approved (3) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06929143 | Pre-clinical | Active |
| NCT05705258 | Pre-clinical | Recruiting |
| NCT04519619 | Pre-clinical | Recruiting |
| NCT03939767 | Pre-clinical | Completed |
| NCT03290794 | Pre-clinical | Completed |
| NCT02821247 | Pre-clinical | Completed |
| NCT02800642 | Approved | Completed |
| NCT02425501 | Pre-clinical | Completed |
Competing Products
20 competing products in Central Retinal Vein Occlusion